DBV Technologies S.A. (DBVT) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Dbv Technologies Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.396 Welcome to the DBV Technologies three-year results 00:00:05.396 -- 00:00:10.520 from the Open Label Extension to Epitope Phase 3 Trial Conference 00:00:10.520 -- 00:00:12.042 Call. 00:00:12.042 -- 00:00:15.505 All participants will be in a listen-only mode. 00:00:15.505 -- 00:00:20.830 Should you need assistance, please signal a conference specialist by pressing 00:00:20.830 -- 00:00:24.493 the star key followed by zero. 00:00:24.493 -- 00:00:29.701 After today's presentation, there will be an opportunity to ask questions, To 00:00:29.701 -- 00:00:34.807 ask a question, you may press star then one on your telephone 00:00:34.807 -- 00:00:36.329 keypad. 00:00:36.329 -- 00:00:41.495 To withdraw your question, please press star then two. 00:00:41.495 -- 00:00:45.577 Please note, this event is being recorded. 00:00:45.579 -- 00:00:50.805 I would now like to turn the conference over to Katie Matthews, Investor Relations. 00:00:50.805 -- 00:00:52.808 Please go ahead. 00:00:52.808 -- 00:00:58.074 Thank you. This afternoon, DBV Technologies issued a press release announcing 00:00:58.074 -- 00:01:03.081 year three results from our ongoing open-label extension to the epitope 00:01:03.081 -- 00:01:08.325 phase three trial, DBV's prior phase three efficacy study, which evaluated vascular 00:01:08.325 -- 00:01:13.630 peanuts in toddlers ages one to three years old, as well as data from epitopes 00:01:13.630 -- 00:01:17.513 supporting a potential labeling approach for vascular peanuts. 00:01:17.513 -- 00:01:22.618 This press release is available in the press releases section of the DBV Technologies 00:01:22.618 -- 00:01:27.782 website. Before we begin, please note that today's call may include a number 00:01:27.782 -- 00:01:32.997 of forward-look...